En Es
Categories

Industry News

ERBA Mannheim Opens New Subsidiary in Brazil

By Labmedica International staff writers
12 Sep 2019

Image: Erba Mannheim Brazil, a subsidiary of Erba Mannheim, will be located in Nova Lima, Brazil (Photo courtesy of Shutterstock).ERBA Mannheim has expanded its global footprint by opening a new subsidiary in Brazil. The new organization, Erba Mannheim Brazil, will be headquartered in Nova Lima, north of the nation’s capital, will sell a full range of blood and urine test automation solutions in clinical chemistry, hematology, hemostasis, immunoassay, urinalysis, diabetes, critical care and microbiology.

“This new operation significantly enhances our footprint in LATAM,” said Nikhil Vazirani, MD of Erba Mannheim. “We have an excellent team who are looking forward to helping improve workflow and quality whilst reducing cost and turnaround time of Brazilian labs.”

“We are very excited to be able to serve our customers and support our channel partners from within Brazil,” said Tarcisio Vilhena, Brazil country manager. “We have a dedicated team ready to support our customers with application and service expertise as well as sales and marketing support. From the simplest semi-automatic system to the impressive sophistication of our future NEXUS range, we are committed to help improve the lives of millions in Brazil through high quality, affordable automation.”

Erba Mannheim Brazil also showcased key products, including XL200 and XL640 clinical chemistry instruments, LAURA XL automatic urinalysis system, Elite 580 and H560 automatic hematology analyzers and the ECL760 automatic coagulation analyzer, at the 53rd Brazilian Congress of Clinical Pathology in Rio Janeiro, held September 24-27, 2019.



E-mail Print
FaceBook Twitter Google+ Linked in

ERBA MANNHEIM

Erba Mannheim is an IVD solutions provider focused on improving health outcomes in developing nations. Originally founded in India by Suresh Vazirani and now with operations in Europe and the US, Erba provides hospitals and labs with a full range of diagnostic instruments, reagents and support services to more than 100 countries.
Silver member
More info

More articles about ERBA MANNHEIM

16 Jun 2017
Transasia Showcases Clinical Lab Solutions at APPI 2017
Transasia Bio-Medicals Ltd., an in-vitro diagnostic company, will be the technology partner as well as principal partner of the 4th Annual Conference hosted by the Association of Practicing Pathologists of India (APPI-Mumbai), held June 16-18, 2017, in Mumbai, India.
Read More

Additional news

06 Dec 2021
IHF to Launch Geneva Centre of Healthcare Leadership for Sustainability
The International Hospital Federation (IHF; Geneva, Switzerland) is preparing to launch the Geneva Centre of Healthcare Leadership for Sustainability (the Centre) in 2022 in response to the need for hospitals and healthcare services to address climate change.
Read More
06 Dec 2021
Global Mammography Market to Reach USD 3.4 Billion in 2028 Due To Increasing Prevalence of Breast Cancer
The global mammography market is expected to reach USD 3.4 billion in 2028, driven by the increasing prevalence of breast cancer across the globe, rising government fund for ongoing research on breast cancer, and increasing public awareness about cancer. The market growth is being fueled further by increasing number of screening programs and campaigns to create awareness about breast cancer, improving healthcare infrastructure and facilities, and technological advancements in breast imaging techniques.
Read More
03 Dec 2021
Global HBA1c Laboratory Tests Market Driven by Rise in Diabetic Population
The global HBA1c laboratory tests market is projected to expand at a significant pace over the coming years, driven by an increase in the prevalence of diabetes, rise in prescription rate of HBA1c tests by physicians, low price of tests, and awareness about complications of high diabetes levels.
Read More
02 Dec 2021
Roche Completes Acquisition of TIB Molbiol Group
Roche (Basel, Switzerland) has completed its share purchase agreement to acquire 100% of the outstanding shares of TIB Molbiol Group (Berlin, Germany).
Read More
02 Dec 2021
Siemens Partners with Biotech Company Freenome to Develop Blood Test for Early Breast Cancer Detection
Siemens Healthineers (Erlangen, Germany) and Freenome (South San Francisco, CA, USA) have entered into a collaboration in multiomics and radiomic breast cancer diagnostics to identify suitable markers for early breast cancer detection through blood to augment existing imaging technologies.
Read More
01 Dec 2021
Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing
The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow assay kits, demand growth of point-of-care testing, and rise in adoption of LFA kits due to their advantages over laboratory tests.
Read More
30 Nov 2021
Global Chemiluminescence Immunoassay (CLIA) Analyzers Market to Surpass USD 7.5 Billion by 2025
The global chemiluminescence immunoassay (CLIA) analyzers market is estimated to grow at a CAGR of 6.4% in the forecast period of 2020-2025 to reach USD 7.6 billion by 2025, with the reagents segment anticipated to capture almost three-fourth of the overall CLIA analyzers market and reach USD 5.7 billion by the end of 2025.
Read More
29 Nov 2021
Global Fluoroscopy Equipment Market to Top USD3.5 Billion by 2031 Due to Demand for Multipurpose Imaging Tools
The global fluoroscopy equipment market is projected to grow at a CAGR of 6% from an estimated USD 1.9 billion in 2021 to surpass USD 3.5 billion by the end of 2031, driven by surging applications of fluoroscopy equipment across various medical fields such as cardiology, nephrology, urology, and others.
Read More
25 Nov 2021
Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases
The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic cases, technological developments in point of care devices and increased investments by the key players.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions